Adverse events, tolerability, acceptability of study procedures and concomitant medications at follow up
| Colchicine group (n=113) | Placebo group (n=111) | P-value | |
|---|---|---|---|
| Any adverse event | 17 | 21 | |
| Re-admission to hospital | 3 | 12 | |
| Adverse event not requiring hospitalisation | 151 | 9 | |
| Gastrointestinal | 12 | 6 | |
| Other2 | 3 | 3 | |
| Discontinued treatment | 5 | 3 | |
| Took≥25 days of study treatment | 104 | 103 | |
| Morisky Medication Adherence score | |||
| Willing to continue with study medication | |||
| Other medications being taken at follow up3 | |||
| Aspirin | 112 (99%) | 109 (100%)3 | |
| Second anti-platelet agent | 108 (96%) | 108 (99%)3 | |
| Statin | 109 (96%) | 107 (98%)3 | |
| Beta-blocker | 107 (95%) | 107 (98%)3 | |
| ACE inhibitor or ARB | 106 (94%) | 104 (95%)3 | |